Skip to main navigation Skip to main content
  • KSPTM
  • E-Submission

PHD : Parasites, Hosts and Diseases

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

1
results for

"mice (BALB/c)"

Article category

Keywords

Publication year

Authors

"mice (BALB/c)"

Original Article
Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice
Ghassem Solgi, Amina Kariminia, Khossro Abdi, Majid Darabi, Behnaz Ghareghozloo
Korean J Parasitol 2006;44(1):55-61.
Published online March 20, 2006
DOI: https://doi.org/10.3347/kjp.2006.44.1.55

For treating Leishmania major infection in BALB/c mice, we used thalidomide in conjunction with glucantime. Groups of mice were challenged with 5 × 103 metacyclic promastigotes of L. major subcutaneously. A week after the challenge, drug treatment was started and continued for 12 days. Thalidomide was orally administrated 30 mg/kg/day and glucantime was administrated intraperitoneally (200 mg/kg/day). It was shown that the combined therapy is more effective than single therapies with each one of the drugs since the foot pad swelling in the group of mice received thalidomide and glucantime was significantly decreased (0.9 ± 0.2 mm) compared to mice treated with either glucantime, thalidomide, or carrier alone (1.2 ± 0.25, 1.4 ± 0.3, and 1.7 ± 0.27 mm, respectively). Cytokine study showed that the effect of thalidomide was not dependent on IL-12; however, it up-regulated IFN-γ and down-regulated IL-10 production. Conclusively, thalidomide seems promising as a conjunctive therapy with antimony in murine model of visceral leishmaniasis.

Citations

Citations to this article as recorded by  Crossref logo
  • Deciphering Molecular Mechanisms of Cutaneous Leishmaniasis, Pathogenesis and Drug Repurposing through Systems Biology
    Fatemeh Saberi, Zeinab Dehghan, Zahra Taheri, Tayyebeh Pilehchi, Hakimeh Zali
    Iranian Biomedical Journal.2024; 28(4): 179.     CrossRef
  • A standardized intraperitoneal Glucantime™ for experimental treatment of cutaneous leishmaniasis caused by Leishmania amazonensis in BALB/c mice
    Aline Ávila Brustolin, Nathália Martins Franzói, Áquila Carolina Fernandes Herculano Ramos-Milaré, Cínthia Akemi Tanoshi, Camila Alves Mota, Izabel Galhardo Demarchi, Maria Valdrinez Campana Lonardoni, Thaís Gomes Verzignassi Silveira
    Experimental Parasitology.2022; 236-237: 108259.     CrossRef
  • Effect of Synergism of Thalidomide and Liposomal Amphotericin-B on Leishmania tropica and Leishmania donovani Promastigote
    Nasma I. Al-Mamary, Haitham L. Al-Hayali
    Bionatura.2022; 7(2): 1.     CrossRef
  • Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice
    Alexandre C. Santana, Sabrina Degaspari, Sergio Catanozi, Humberto Dellê, Larissa de Sá Lima, Cleonice Silva, Paula Blanco, Kim Solez, Cristoforo Scavone, Irene L. Noronha
    Nephrology Dialysis Transplantation.2013; 28(5): 1140.     CrossRef
  • Immunomodulation by chemotherapeutic agents against Leishmaniasis
    Piu Saha, Debanjan Mukhopadhyay, Mitali Chatterjee
    International Immunopharmacology.2011; 11(11): 1668.     CrossRef
  • Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis
    Shraddha A. Sane, Nishi Shakya, Suman Gupta
    Experimental Parasitology.2011; 127(2): 376.     CrossRef
  • Potential utility of hyperbaric oxygen therapy and propolis in enhancing the leishmanicidal activity of glucantime
    Diana Copi Ayres, Thiago Antonio Fedele, Maria Cristina Marcucci, Selma Giorgio
    Revista do Instituto de Medicina Tropical de São Paulo.2011; 53(6): 329.     CrossRef
  • Anni 2.0: a multipurpose text-mining tool for the life sciences
    Rob Jelier, Martijn J Schuemie, Antoine Veldhoven, Lambert CJ Dorssers, Guido Jenster, Jan A Kors
    Genome Biology.2008;[Epub]     CrossRef
  • 8,836 View
  • 94 Download
  • Crossref